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Background. We investigated antibody persistence in children 1 year after 2 doses of either an AS03B-adjuvanted
split-virionornonadjuvantedwhole-virionmonovalentpandemic inﬂuenzavaccineand assessedtheimmunogenicity
and reactogenicity of a subsequent dose of trivalent inﬂuenza vaccine (TIV).
Methods. Children previously immunized at age 6 months to 12 years in the original study were invited to
participate.Aftera blood sample was obtainedtoassesspersistenceofantibodyagainstswine inﬂuenzaA/H1N1(2009)
pandemic inﬂuenza, children received 1 dose of 2010/2011 TIV, reactogenicity data were collected for 7 days, and
another blood sample was obtained 21 days after vaccination.
Results. Of 323 children recruited, 302 received TIV. Antibody persistence (deﬁned as microneutralization
[MN] titer $1:40) 1 year after initial vaccination was signiﬁcantly higher in the AS03B-adjuvanted compared with
the whole-virion vaccine group, 100% (95% conﬁdence interval [CI], 94.1%–100%) vs 32.4% (95% CI, 21.5%–44.8%)
in children immunized ,3 years old and 96.9% (95% CI, 91.3%–99.4%) vs 65.9% (95% CI, 55.3%–75.5%) in
those 3–12 years old at immunization, respectively (P , .001 for both groups). All children receiving TIV had
post-vaccination MNtiters $1:40.AlthoughTIV was welltoleratedin all groups,reactogenicity in children,5 years
old was slightly greater in those who originally received AS03B-adjuvanted vaccine.
Conclusions. This study provides serological evidence that 2 doses of AS03B-adjuvanted pandemic inﬂuenza
vaccine may be sufﬁcient to maintain protection across 2 inﬂuenza seasons. Administration of TIV to children who
previously received 2 doses of either pandemic inﬂuenza vaccine is safe and is immunogenic for the H1N1 strain.
During the ﬁrst and second waves of infection in the
2009–2010 A/H1N1(2009) inﬂuenza pandemic, there
were at least 18337 deaths globally [1, 2]. The United
Kingdom Department of Health purchased 2 pandemic
monovalent inﬂuenza vaccines (a nonadjuvanted cell
culture-derived whole-virion vaccine and an AS03B-
adjuvantedegg culture-derived split-virion vaccine)that
were used during the national pandemic inﬂuenza
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immunogenicity of a 2-dose regimen of these vaccines in
943 children aged 6 months to 12 years old. We found the
AS03B-adjuvanted vaccine more immunogenic, especially in
younger children (microneutralization [MN] titer $1:40 in
children under 3 years of age was 98.2% vs 80.1%) [3].
In the initial stage of the 2009 pandemic, at least 25000 children
at increased clinical risk from inﬂuenza infection received
a 2-dose regimen of monovalent H1N1 vaccine (R. Pebody,
personal communication) [4, 5]. Subsequently, the United
Kingdom recommended single-dose immunization for all chil-
dren aged 6 months to 5 years after review of early reactogenicity
data [3, 6]. Analyses have since demonstrated the AS03B-
adjuvanted vaccine to be effective against the pandemic H1N1
strain [7–10], even after a single dose in young children [11].
However, there are no published data that assess the persistence
of antibody in children immunized against the novel H1N1 virus
to help guide future pandemic vaccination policy [12].
Concerns have arisen over both the reactogenicity and im-
munogenicity of the seasonal trivalent inﬂuenza vaccine (TIV)
in those who have previously received monovalent pandemic
vaccine, but to date this has not been studied in a clinical trial
[13–15]. Recent analyses have shown signiﬁcantly lower immu-
nogenicity to monovalent pandemic inﬂuenza vaccines in those
who had received previous TIV, but it is unknown whether the
reverse is true [13–15].
This follow-on study investigated both the persistence of anti-
H1N1 antibody 1 year after immunization with the pandemic
vaccines and the immunogenicity of the H1N1 component and
reactogenicity of a subsequent dose of TIV in these children.
METHODS
Study Design
This was a multicenter, open-label, phase IV study following on
from a randomized trial. At visit one, a blood sample assessed
persistence of antibodies to H1N1. A single, 0.5-mL in-
tramuscular dose of TIV was administered into the deltoid.
A second blood sample was taken 21 days (27 to +14 days) later
days later. For those not wishing to receive the study vaccine,
parents could consent to the ﬁrst blood test alone. For 7 days
after administration of TIV, parents used daily diary cards to
record the axillary temperature, injection site reactions, systemic
symptoms, and use of antipyretic medication (Supplementary
Table 1). All medical consultations between study immuni-
zation and the second study visit were recorded. Serum analysis
was undertaken centrally, using standard methods [3, 16, 17].
The study was registered at ClinicalTrials.gov (NCT01239537),
conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice, and approved by the UK Medicines and
Healthcare Products Regulatory Agency (EudraCT No. 2010-
022817-24), the Oxfordshire Research Ethics Committee A (10/
H0604/81), and local National Health Service (NHS) organ-
izations.
Participants
Between 11 November and 2 December 2010, 323 children
who completed the original study [3]a n dw e r en o wb e t w e e n
17 months and 13 years old were recruited at 5 UK sites. In-
clusion, exclusion, and temporary exclusion criteria are shown
in Supplementary Table 2A and for the original study in Sup-
plementary Table 2B. The original study recruited healthy
children; however, high-risk children, such as asthmatics, were
not excluded unless considered immunosuppressed. Allocation
was to the same group as in the original study, in which they
hadbeenstratiﬁedforage (,3or$3years old)andrandomized
to receive either pandemic vaccine (consort diagram, Figure 1)
[3]. All vaccinated children received a single dose of the TIV
(Fluarix; GlaxoSmithKline). Parents or guardians gave written
informed consent, and children aged $7 years gave verbal assent.
Vaccine
The TIV Fluarix (GlaxoSmithKline Biologicals) contained in-
activated split-virion inﬂuenza virus propagated in fertilized
hens’ eggs with 15 lg of hemagglutinin antigen for each strain
in a 0.5-mL dose [18] .T h e3W o r l dH e a l t hO r g a n i z a t i o n -
recommended strains were A/California/7/2009 (H1N1)-derived
strain, A/Perth/16/2009 (H3N2)-like strain, and B/Brisbane/60/
2008 [18, 19].
Study End Points
The primary end points were as follows: (1) persistence of
microneutralizing antibody titers against pandemic virus, mea-
sured as the percentage of children with MN titers $1:40 at
1 year compared with 3 weeks after 2 doses of pandemic mono-
valent inﬂuenza vaccine [3]; (2) immunogenicity of TIV against
pandemic virus 3 weeks after vaccination, measured as the per-
centage of children who seroconverted and had a postvacci-
nation MN titer $1:40 or hemagglutination inhibition (HI)
titer $1:32 (against H1N1 strain) or who were seropositive
before vaccination and had a 4-fold increase in titer; and (3)
reactogenicity after TIV, measured as the percentage of chil-
dren experiencing fever, local reactions, and nonfebrile systemic
symptoms within 7 days after vaccination. Different systemic
symptoms were solicited in those under and over 5 years to reﬂect
differences in ability to articulate symptoms (Supplementary
Table 1; secondary end points, Supplementary Table 3).
Statistical Analysis
Data were analyzed in groups based on a child’s vaccine allo-
cation and original study age [3]. For analysis of reactogenicity,
age was divided into ,5a n d$5 years of age at the time of
TIV. Proportions with titers above MN and HI thresholds, with
662 d CID 2012:54 (1 March) d Walker et alFigure 1. Enrollment and follow-up of study participants. Groups were allocated as in the original study, first split into those receiving either the whole-virion or the AS03B-adjuvanted vaccine and then
further divided into those ,3 and $3–12 years of age at the time of the original study [3]. Annotations (a), (b), and (c) highlight the participants on whom analysis was performed: (a) indicates persistence
of antibody levels; (b) and (c), immunogenicity and reactogenicity after trivalent influenza vaccine (TIV) analysis, respectively.
1In the original study, this participant accidently received the incorrect vaccine
[3] (whole-virion instead of AS03B-adjuvanted vaccine, as per randomization) and was therefore moved to the whole-virion group for follow-on in this study.
2Participant was mistakenly put into the older
age group in the original study but was ,3 years of age by 1 day, should have been in the younger age group, and was moved there for analysis in this follow-on study [3].
3Six participants who did not
complete all of the study procedures in the original study and therefore should have been excluded from this follow-on study were approached in error [3].
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34-fold changes and with adverse reactions were calculated with
exact 95% conﬁdence intervals (CIs) in each group. Differences
between groups were assessed using Fisher’s exact test. To assess
4-fold changes from before to after TIV, samples were further
titrated if necessary. Geometric mean titers (GMTs) and fold
changes were calculated for HI with 95% CIs. Post-TIV samples
with high MN titers were not diluted further to obtain precise
titers (unnecessary for study end points), and therefore GMT
data are not presented. Where results were above or below assay
limits they were set to double or half the limit, respectively.
Normal error regression on logged titers was used to compare
groups. Reverse cumulative distribution curves were constructed
to describe the titer distributions in each group. Comparisons
were made between pandemic vaccine groups in which ages
could be combined as well as between pandemic vaccine groups
within age groups. Signiﬁcance was set at 5%; analysis was by
modiﬁed intention to treat and was performed using Stata
software, version 10.0 (StataCorp).
Sample Size
A target recruitment rate of 40% would give 90 participants
for each vaccine group aged ,3 and 100 for each aged $3. This
would give precision (95% CI) around a proportion of 80% of
70%–88% and a proportion of 80% that would be detected as
different from 95% (80% power, 5% signiﬁcance). In the
original study, children who did not seroconvert after 2 doses
were offered an additional vaccine dose. Those who received
it were excluded from this study [3]. To compensate for
possible resulting bias, antibody titers measured after 2 doses
from an appropriate number of these subjects selected at
random were included in the analysis.
RESULTS
Of 943 children enrolled in the original study, 894 were eli-
gible for enrollment, of whom 323 were recruited (36%)
(Figure 1)[ 3]. Three hundred four provided a sample for
antibody persistence, of whom 302 received TIV (2 withdrew
before receipt of TIV), and 19 took part in the persistence
study alone.
Persistence of Antibody Against A/H1N1(2009) Virus
The mean interval from second dose of pandemic vaccine to
persistencebloodtest was 387 days (range, 365–429days). Three
hundred eighteen samples were available for analysis (Figure 1
and Supplementary Table 4A The persistence of antibody levels
1 year after vaccination, deﬁned by MN titer $1:40, was sig-
niﬁcantly higher in the AS03B-adjuvanted vaccine group than
the whole-virion vaccine group, particularly in the younger
age group (P , .001 in both age groups) (Table 1). In the
original study, 100% of children in both age groups given
AS03B-adjuvanted vaccine had an MN titer $1:40 3 weeks
after vaccination (95% CIs, 94.1%–100% and 96.3%–100%
in the younger and older groups, respectively). One year after
vaccination, these ﬁgures were 100% (95% CI, 94.1%–100%)
and 96.9% (95% CI, 91.3%–99.4%). In those originally given
whole-virion vaccine, 82.4% (95% CI, 71.2%–90.5%) and
94.5% (95% CI, 87.6%–98.2%) had an MN titer $1:40 3 weeks
after the initial vaccination, but by 1 year these had fallen to 32.4%
(95% CI, 21.5%–44.8%) and 65.9% (95% CI, 55.3%–75.5%) in
the younger and older groups, respectively (Table 1). These
ﬁndings are illustrated by the reverse cumulative distribution
curves (Figure 2).
Table 1. Antibody Persistence (by Microneutralization [MN] and Hemagglutination Inhibition [HI] Titers) 3 Weeks and 1 Year After
2 Doses of a Nonadjuvanted Whole-Virion or an AS03B-Adjuvanted Split-Virion Monovalent Pandemic Influenza Vaccine, by Age Group
Age
Group, y
a
Total
No.
MN $40
MN Change Between
Time Points
MN 1 y Later,
Geometric
Mean (95% CI)
b
HI $32
HI Change Between
Time Points
3 wk After
2nd Pandemic
Dose 1 y Later
b
From $40
to ,40
From ,40
to $40
3 wk After
2nd Pandemic
Dose 1 y Later
b
From $32
to ,32
From ,32
to $32
Whole-Virion Vaccine
,3 68 56 (82.4) 22 (32.4) 35 1 33.6 (23.8–47.5) 40 (58.8) 43 (63.2) 8 11
3–12 91 86 (94.5) 60 (65.9) 26 0 66.9 (53.1–84.2) 82 (90.1) 72 (79.1) 14 4
All 159 142 (89.3) 82 (51.6) 61 1 49.8 (40.7–61.0) 122 (76.7) 115 (72.3) 22 15
AS03B-Adjuvanted Vaccine
,3 61 61 (100) 61 (100) 0 0 411.9 (332.5–510.2) 61 (100) 60 (98.4) 1 0
3–12 98 98 (100) 95 (96.9) 3 0 287.6 (230.5–358.9) 98 (100) 95 (96.9) 3 0
All 159 159 (100) 156 (98.1) 3 0 330.1 (281.3–387.4) 159 (100) 155 (97.5) 4 0
Unless otherwise speciﬁed, data represent No. (%) of children.
Abbreviation: CI, conﬁdence interval.
a Age groups based on age at original study [3].
b P , .001 for all comparisons between 1-year values for whole-virion and AS03B-adjuvanted vaccines.
664 d CID 2012:54 (1 March) d Walker et alThe proportion of children with titers above the putative
protective threshold were comparable by both HI and MN titers
(HI $1:32 and MN $1:40), except in the serum samples from
those in the younger age group who had received the whole-
virion vaccine, in which the percentage of children with an
HI $1:32 increased from 58.8% (95% CI, 46.2%–70.6%) 3 weeks
after initial vaccination to 63.2% (95% CI, 50.7%–74.6%) at
1 year (Table 1 and Figure 2). The HI titers of 11 of 68 younger
and 4 of 91 older children in the whole-virion group were
low (,1:32) 3 weeks after the second dose of pandemic vaccine
but higher ($1:32) 1 year later (Table 1); however, MN titers
did not rise in these children (Table 1). When considering
only children who responded well to the initial whole-virion
vaccination (HI titer $1:32 at 3 weeks), the percentages at 1 year
with HI titers $1:32 dropped consistently from 100% in
both age groups to 80% (95% CI, 64.4%–90.9%) and 82.9%
(95% CI, 73%–90.3%) in the younger and older groups,
respectively (Supplementary Table 5).
Immunogenicity of Trivalent Influenza Vaccine
Three hundred two children received the 2010/2011 TIV
(Figure 1 and Supplementary Table 4B). Across all groups
theaverage HI GMT increased by 10.7 to 16.7 foldincrease in
HI GMT (Table 2). All children had a post-vaccination MN
$1:40 and an HI titer $1:32 (Table 2). However, HI GMTs
were signiﬁcantly higher (P , .001) in those who initially
received AS03B-adjuvanted vaccine compared with those re-
ceiving whole-virion vaccine, and these data are illustrated by the
reverse cumulative distribution curves (Table 2 and Figure 3).
Reactogenicity of Trivalent Influenza Vaccine
Diaries were returned for 295 children (Figure 1). There were
no serious adversereactions.Redness and severelocalsymptoms
weremorefrequent inchildren ,5 yearsoldwhohadpreviously
received the AS03B-adjuvanted vaccine than the whole-virion
vaccine (P , .05) (Supplementary Table 6). For all other soli-
cited local and systemic symptoms, there were no signiﬁcant
differences between the vaccine groups. There were 2 signiﬁcant
differences (P , .05) between age groups: pain was reported
more frequently in those .5 years of age, and fever $38Cw a s
reported more frequently in those ,5 years of age, regardless of
preceding pandemic vaccine (Supplementary Tables 6 and 7).
Long-Term Safety Monitoring
No solicited adverse events (ie, inﬂuenzalike illness, adverse
events of special interest) were reported to have occurred in
the year after receipt of either pandemic inﬂuenza vaccine
(Supplementary Table 8).
Figure 2. Hemagglutination inhibition (HI) and microneutralization (MN) titer reverse cumulative distribution (RCD) curves 3 weeks and 1 year after
pandemic vaccination by age and vaccine. (Note: MN titers are shown only to .320, the analysis end point for serum samples in the follow-on study.)
Pandemic Inﬂuenza Immunization d CID 2012:54 (1 March) d 665DISCUSSION
Persistence of Antibody
Almost all children who received the AS03B-adjuvanted vaccine
retained MN titers $1:40 1 year later, compared with 52% of
those previously immunized with whole-virion vaccine
(Table 1). Other studies have shown persistence of anti-H1N1
titer at 6 months after AS03A-adjuvanted vaccine [15, 20].
However, the pediatric study used the full adult dose (0.5 mL)
[15],notthehalfdoserecommendedsinceSeptember2009[21],
and the data do not extend to a second inﬂuenza season (AS03A
and AS03B differ only in that ‘‘B’’ denotes pediatric adjuvant
dose). A recent analysis of the vaccine effectiveness of either
monovalent pandemic inﬂuenza vaccination in 2009/2010,
TIV in 2010/2011, or both in protecting against A/H1N1 (2009)
virus during the winter of 2010–2011 suggested that single-dose
pandemic vaccine protection may not last across seasons, al-
thoughonly20% ofthose studied werechildren[22]. These data
are supported by a recent Canadian study showing that on-
ly 46% of children maintained protective levels of antibody
1 year after receiving a single dose of AS03B-adjuvanted pan-
demic inﬂuenza vaccine [23]. Our data suggest that a 2-dose
regimen of AS03B-adjuvanted pandemic vaccine may have been
more effective across inﬂuenza seasons.
In the initial stages of a pandemic, there is high likelihood
of both a limited supply of pandemic antigen and logistical
difﬁculties in administering a 2-dose immunization regimen.
However, the lower antibody responses with a single dose re-
ported by some [23] may limit protection for a second wave
compared with the 2-dose regimen reported here. In a sub-
sequent pandemic, policymakers might therefore plan to ini-
tially give a single dose of an adjuvanted inﬂuenza vaccine to
all age groups for the ﬁrst wave, which is of proven effectiveness
[7–11], followed by a booster dose of the vaccine at the time
of the second pandemic wave, thus providing capacity during
the ﬁrst wave and time for vaccine production for the sub-
sequent booster dose.
Although there is less published data, MN titers are likely to
be a better correlate of protection against inﬂuenza than HI
titers [24]. In the younger vaccine group who received the
whole-virion vaccine in 2009, the proportion with MN titers
$1:40 fell from 82.4% 3 weeks post-vaccination to 32.4% at
1 year. Unexpectedly, the proportion with HI titers $1:32 re-
mained comparable (58.8%–63.2%) during the same period
(Figure 2 and Table 1). This disparity between MN and HI titers
was not seen in other groups or in previous studies [3, 16, 25, 26].
Although the higher HI titers are perhaps most likely to have
been caused by wild-type H1N1 infection in those who had
apreviouslypoorresponse totheinitialvaccine course(Table1),
it is difﬁcult to propose a biologically plausible explanation as
to why their MN titers decreased. Although no inﬂuenza-like
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666 d CID 2012:54 (1 March) d Walker et alillnesses were reported, it is possible that these were mild or
subclinical H1N1 infections, a possibility compatible with
national seroepidemiological evidence that showed 26% of
.5-year-olds and 53% of 5–14-year-olds were infected in the
second wave [26]. Differences between MN and HI trends could
also occur because MN measures a broader range of antibodies
that neutralize the virus, whereas HI measures a limited set of
epitopes involved in hemagglutination. One possible expla-
nation is that, in some vaccinated children, responses to
hemagglutinin predominate on exposure to infection. Further
work will be required to assess the correlation between MN
titers and protection from inﬂuenza.
Immunogenicity of Seasonal Trivalent Influenza Vaccine
Findings of other studies have suggested that prior receipt of
TIV may reduce the immunogenicity of pandemic monovalent
inﬂuenza vaccines [14, 15]. Despite no control group, our data
do not suggest that the reverse is true. In all groups, the GMTs
were higher than those seen 3 weeks after the original vaccina-
tion course. A higher anti-H1N1 titer before TIV was associated
with a higher titer after vaccination (data not shown). In the
younger age group, previous receipt of an AS03B-adjuvanted
vaccine seems to enhance the serological response to a dose of
a nonadjuvanted vaccine 1 year later, even allowing for the pre-
vaccination titers (P 5 .03) (data not shown). This result could
be explained by an enhanced priming mechanism in the
adjuvanted vaccine group (Figure 3). Therefore, it will be
informative todeterminewhethertherewasanyeffectofvaccine
group on responses to the nonpandemic inﬂuenza strains
included in the TIV.
Reactogenicity of Seasonal Trivalent Influenza Vaccine
Mild reactogenicity was seen in all groups after TIV. Four
children ,5 years of age had a temperature of $39C, 1 in the
AS03B-adjuvanted and 3 in the whole-virion vaccine groups.
No febrile convulsions were reported.
Long-Term Safety Monitoring
No adverse events of special interest occurred in the year after
pandemic vaccination, although the study was not powered to
detect rare events. Despite recent European reports of narcolepsy
in children and young adults who received AS03B-adjuvanted
vaccine [27, 28], there has been no UK signal detected from
passive surveillance [29].
Limitations and Applicability
First, the main limitation was lower recruitment than antici-
pated, possibly owing to low public anxiety regarding inﬂuenza
during the recruitment window. Despite this, the demo-
graphics were similar between follow-on and original studies
(Supplementary Table 9), apart from comparatively fewer
,3-year-old children being recruited in the follow-on study
Figure 3. Hemagglutination inhibition (HI) and microneutralization (MN) titer reverse cumulative distribution curves before and after trivalent influenza
vaccine (TIV) by age and vaccine. (Note: MN titers are shown to .5120, the analysis end point for serum samples in the follow-on study.)
Pandemic Inﬂuenza Immunization d CID 2012:54 (1 March) d 667and one site recruiting less well than in the original study.
Although this loss of power is relevant when interpreting
differences between groups, the resultant reduction in de-
tectable difference is not marked (3%), and actual differences
seen between the vaccine groups were generally large. Second,
we have currently assessed only the immunogenicity of the
H1N1 component of TIV. Assessment of the other 2 TIV strains
isplanned when fundingis available.The relevance of our results
to adjuvanted polyvalent vaccines remains uncertain. Third,
owing to funding limitations, this study was limited to the
children in our original study, who all received 2 doses of
pandemic inﬂuenza vaccine rather than the 1-dose regimen
subsequently recommended for the AS03B-adjuvanted vaccine
in the national program for healthy children in the United
Kingdom[3,6].ThemajorityofchildrenintheUnitedKingdom
w h ow e r ev a c c i n a t e dw i t ha d j u v a n t e dp a n d e m i cv a c c i n er e -
ceived only 1 dose, and they are likely to have lower antibody
persistence [30].
Eighty-one percent of the children known to have died in the
2009/2010 UK winter season from pandemic H1N1 infection
were in clinical risk groups [31]. More than 25000 at-risk
children received a 2-dose vaccination regimen similar to that
received by our cohort (R. Pebody, personal communication) [4].
While our original study did not speciﬁcally recruit at-risk
children (although some were included, such as asthmatics), our
data are directly applicable to the at-risk children who are most
likely to die of pandemic H1N1 infection.
CONCLUSION
Children who received 2 doses of AS03B-adjuvanted pandemic
inﬂuenza vaccine showed persistence of antibody above putative
protective thresholds 1 year after vaccination compared with
only approximately half of those who received the whole-
virion vaccine. It is safe to administer trivalent seasonal inﬂuenza
vaccine to children who received a 2-dose regimen of the pan-
demic inﬂuenza vaccines used in the United Kingdom in 2009,
and this increased children’s antibody levels against the H1N1
component of the vaccine. This study provides serological
evidence that a 2-dose regimen of vaccination with an AS03B-
adjuvanted pandemic inﬂuenza vaccine may be sufﬁcient to
maintain protection across 2 inﬂuenza seasons. Pandemic
planners may consider initially administering a single dose of
adjuvanted pandemic vaccine to allow higher population cov-
erage from limited dose supply, followed by a booster dose in
the next season if the same strain is circulating.
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